US Progesterone Prices Rise 1.16% as Freight Inflation Lifts Landed Costs

US Progesterone CFR Los Angeles prices rose 1.16% in June 2026, according to ChemAnalyst data, as rising logistics costs and steady downstream procurement combined to firm market sentiment. Early June saw import availability remain balanced, but freight inflation and insurance-driven premium increases began to lift landed costs mid-month. Progesterone manufacturers largely maintained routine production schedules throughout June, while buyers across pharmaceutical and veterinary channels stayed active to preserve continuity of supply. The late-month market tone was moderately firm, with procurement continuing despite higher landed offers, supporting exporters’ willingness to hold firmer spot quotations into the close of the month.

Progesterone demand patterns were broadly steady across core end-use sectors in June. Hormone replacement therapy (HRT) procurement sustained regular Progesterone volumes with formulators maintaining HRT formulations, while fertility and assisted reproductive treatment buyers continued routine Progesterone purchasing to support IVF and API production. Contraceptive and gynecology medicine uptake likewise held at baseline levels, and veterinary pharmaceutical demand for Progesterone-based reproductive healthcare and estrus synchronization remained consistent. In contrast to demand stability, freight dynamics exerted an outsized influence on landed-cost calculations—freight to the US West Coast rose notably in June, a factor cited by buyers when timing call-offs, per ChemAnalyst analysis.

Upstream Progesterone feedstocks largely avoided disruption during June, with diosgenin-derived precursors, cholesterol derivatives and soy-derived phytosterols remaining available and preventing major production constraints. However, industrial solvent costs, notably routes tied to Gulf-origin isopropanol, showed upward pressure and represent a potential squeeze on Progesterone reagent and solvent costs if shipping risk escalates. Logistics and insurance changes were a clear production and sourcing consideration: mid-June war-risk premium adjustments for routes near the Gulf of Aden pushed charter costs higher, and suppliers managed inventories cautiously ahead of scheduled autumn maintenance at origin fermentation facilities and late-summer downstream turnarounds.

Progesterone market movement through June reflected the timeline of those logistical developments rather than abrupt swings in underlying API demand. Early-month balancing of imports gave way to progressively firmer landed offers as container freight rose and insurers lifted war-risk premiums; Progesterone manufacturers nonetheless kept regular runs and suppliers guarded Progesterone spot availability. The freight increase of note was recorded in June, and a broader freight surge tied to elevated war-risk premiums and charter rates has been reported as a significant upward pressure on delivered Progesterone costs, per ChemAnalyst analysis. Progesterone buyers largely prioritized supply security, smoothing call-offs through the month.

Looking ahead, ChemAnalyst analysis points to a mixed near-term outlook: a slight dip in July–August followed by modest gains through September–December based on current market trends. Key drivers include higher logistics and war-risk premium-driven landed Progesterone costs, steady baseline pharmaceutical and veterinary demand, seasonal maintenance turnarounds that can temporarily curb bulk Progesterone consumption, and the seasonal cycle for refined diosgenin and soy sterols before the next harvest. This projection is subject to market conditions—particularly freight and insurance dynamics—and could shift if shipment risk or feedstock availability changes materially.